Men at Higher Risk for AUR After BoNTA Treatment
Researchers in Taiwan have identified risk factors for adverse events (AEs) from intravesical injections of botulinum toxin A (BoNTA) for refractory idiopathic detrusor overactivity (IDO).
Researchers in Taiwan have identified risk factors for adverse events (AEs) from intravesical injections of botulinum toxin A (BoNTA) for refractory idiopathic detrusor overactivity (IDO).
A recently published study in Annals of Internal Medicine (2010;153:213-221) shows that taking responsibility for medical errors and apologizing to patients leads to fewer lawsuits.
Like Illinois and Georgia before it, the state Supreme Court of Nevada is being asked to decide whether limits on malpractice awards are constitutional.
The Tennessee legislature is considering two bills intended to reform medical malpractice claims.
An investigational drug called pasireotide is effective at reducing cortisol levels in patients with Cushing’s disease, according to the results of a phase 3 trial.
Gen-Probe has submitted a Premarket Approval Application (PMA) to the FDA for its PCA3 assay (Progensa), which may help determine the need for repeat prostate biopsies in men suspected of having prostate cancer.
The FDA has approved the brand name for commercially available Veletri (epoprostenol for injection) for pulmonary arterial hypertension (PAH).
The FDA has proposed withdrawing approval of midodrine, a drug used to treat orthostatic hypotension, because required post-approval studies that verify the clinical benefit of the medication have not been done, the agency announced.
Savient Pharmaceuticals, Inc., of East Brunswick, N.J., has received FDA clearance to market Krystexxa (pegloticase) as a treatment for chronic gout in adult patients refractory to conventional treatment.
The degree of hydronephrosis may predict ureteral stone size, according to a study published in the American Journal of Emergency Medicine (2010;28:813-816).